Venatorx Pharmaceuticals, Inc.

Vicuron Pharmaceuticals Inc.

Timothy Henkel

Christopher J Burns

Daniel C Pevear

Ana Fernandez Casares

Martin Stogniew

Denis Daigle

Daniel McGarry

Jodie Hamrick

Luigi Xerri

Lawrence Rosen

Gerald Brenner

Jean-Baptiste Arlin

Marco Cavaleri

Daniela Jabes

Giorgio Mosconi

Richard J White

Described herein are crystalline forms of (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid. In some embodiments, the crystalline forms are formulated for treating a subject in need thereof with a bacterial infection.

Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof

The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.

Stable pharmaceutical compositions of dalbavancin and methods of administration

Methods of administering dalbavancin for treatment of bacterial infections

Growing community of inventors

Berwyn, PA, United States of America

Timothy Henkel